[Tris(2-hydroxyethyl)ammonium ortho-cresyl acetate inhibits oxidative modification of the low density lipoproteins].
Oxidative modification of low-density lipoproteins (LDLP) may play an important role in the pathogenesis of atherosclerosis. The work deals with the study of the inhibiting effect of tris(2-hydroxyethyl)ammonium orthocresoxyacetate (cresacin) on Cu+2-induced oxidation of human LDLP in vitro. The degree of LDLP oxidation was judged according to the accumulation of diene conjugates in the incubation medium. Inhibition of the degree of LDLP oxidation was found to be dependent on the dose of cresacin. The level of products forming during LDPL oxidation and reacting with thiobarbituric acid was also determined. Like in the previous case, the dose-dependent effect of inhibition of LDLP peroxidation by cresacin was also observed. It is concluded that cresacin is an effective inhibitor of LDLP oxidative modification in vitro.
Korda
M M
MM
Department of Biochemistry, Ternopol Medical Institute, Ukraine.
D000085:Acetates / Q000494:pharmacology*; D000328:Adult; D000975:Antioxidants / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004983:Ethanolamines / Q000494:pharmacology*; D006801:Humans; D015227:Lipid Peroxidation / Q000187:drug effects*; D008077:Lipoproteins, LDL / Q000097:blood*
D000085:Acetates; D000975:Antioxidants; D004338:Drug Combinations; D004983:Ethanolamines; D008077:Lipoproteins, LDL; C047413:crezacin
Tris(2-oksiétil)ammoniĭ ortokrezoksiatsetat ingibiruet okislitel'nuiu modifikatsiiu lipoproteinov nizkoĭ plotnosti.